NCT05045248View on ClinicalTrials.gov

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

April 15, 2021

Study Completion Date

April 15, 2021

Conditions
Myasthenia GravisOcular Myasthenia Gravis
Interventions
DRUG

Apraclonidine Hcl 0.5% Oph Soln

Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye

Trial Locations (1)

1107

American University of Beirut Medical Center, Beirut

All Listed Sponsors
lead

American University of Beirut Medical Center

OTHER

NCT05045248 - Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis | Biotech Hunter | Biotech Hunter